Literature DB >> 22450903

Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors.

Yasushi Hamamoto1, Masaaki Kataoka, Motohiro Yamashita, Naoyuki Nogami, Yoshifumi Sugawara, Toshiyuki Kozuki, Shigeki Sawada, Hiroshi Suehisa, Syuichi Shinohara, Naomi Nakajima, Tetsu Shinkai.   

Abstract

PURPOSE: To identify factors affecting local control of stereotactic body radiotherapy (SBRT) for lung tumors including primary lung cancer and metastatic lung tumors.
MATERIALS AND METHODS: Between June 2006 and June 2009, 159 lung tumors in 144 patients (primary lung cancer, 128; metastatic lung tumor, 31) were treated with SBRT with 48-60 Gy (mean 50.1 Gy) in 4-5 fractions. Higher doses were given to larger tumors and metastatic tumors in principle. Assessed factors were age, gender, tumor origin (primary vs. metastatic), histological subtype, tumor size, tumor appearance (solid vs. ground glass opacity), maximum standardized uptake value of positron emission tomography using (18)F-fluoro-2-deoxy-D: -glucose, and SBRT doses.
RESULTS: Follow-up time was 1-60 months (median 18 months). The 1-, 2-, and 3-year local failure-free rates of all lesions were 90, 80, and 77 %, respectively. On univariate analysis, metastatic tumors (p < 0.0001), solid tumors (p = 0.0246), and higher SBRT doses (p = 0.0334) were the statistically significant unfavorable factors for local control. On multivariate analysis, only tumor origin was statistically significant (p = 0.0027). The 2-year local failure-free rates of primary lung cancer and metastatic lung tumors were 87 and 50 %, respectively.
CONCLUSIONS: A metastatic tumor was the only independently significant unfavorable factor for local control after SBRT.

Entities:  

Mesh:

Year:  2012        PMID: 22450903     DOI: 10.1007/s11604-012-0071-x

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  12 in total

1.  Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.

Authors:  Michael J Burdick; Kevin L Stephans; Chandana A Reddy; Toufik Djemil; Shyam M Srinivas; Gregory M M Videtic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-14       Impact factor: 7.038

2.  The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).

Authors:  Atsuya Takeda; Noriko Yokosuka; Toshio Ohashi; Etsuo Kunieda; Hirofumi Fujii; Yousuke Aoki; Naoko Sanuki; Naoyoshi Koike; Yukihiko Ozawa
Journal:  Radiother Oncol       Date:  2011-08-31       Impact factor: 6.280

3.  Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer.

Authors:  Frank B Zimmermann; Hans Geinitz; Sabine Schill; Anca Grosu; Ulrich Schratzenstaller; Michael Molls; Branislav Jeremic
Journal:  Lung Cancer       Date:  2004-12-19       Impact factor: 5.705

4.  Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer.

Authors:  Atsuya Takeda; Etsuo Kunieda; Toshio Ohashi; Yousuke Aoki; Naoyoshi Koike; Toshiaki Takeda
Journal:  Radiother Oncol       Date:  2011-11       Impact factor: 6.280

5.  Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results.

Authors:  Yasushi Hamamoto; Yoshifumi Sugawara; Takeshi Inoue; Masaaki Kataoka; Takashi Ochi; Tadaaki Takahashi; Shinya Sakai
Journal:  Jpn J Clin Oncol       Date:  2011-01-24       Impact factor: 3.019

6.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.

Authors:  Yasushi Nagata; Kenji Takayama; Yukinori Matsuo; Yoshiki Norihisa; Takashi Mizowaki; Takashi Sakamoto; Masato Sakamoto; Michihide Mitsumori; Keiko Shibuya; Norio Araki; Shinsuke Yano; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

7.  Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients.

Authors:  Joern Wulf; Ulrich Haedinger; Ulrich Oppitz; Wibke Thiele; Gerd Mueller; Michael Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-09-01       Impact factor: 7.038

8.  Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study.

Authors:  Hiroshi Onishi; Tsutomu Araki; Hiroki Shirato; Yasushi Nagata; Masahiro Hiraoka; Kotaro Gomi; Takashi Yamashita; Yuzuru Niibe; Katsuyuki Karasawa; Kazushige Hayakawa; Yoshihiro Takai; Tomoki Kimura; Yutaka Hirokawa; Atsuya Takeda; Atsushi Ouchi; Masato Hareyama; Masaki Kokubo; Ryusuke Hara; Jun Itami; Kazunari Yamada
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

9.  Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Motohiro Yamashita; Tetsu Shinkai; Yoshiro Kubo; Yoshifumi Sugawara; Takeshi Inoue; Shinya Sakai; Shoji Aono; Tadaaki Takahashi; Takatoshi Semba; Kotaro Uwatsu
Journal:  Jpn J Clin Oncol       Date:  2009-10-12       Impact factor: 3.019

10.  Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer.

Authors:  Haeyoung Kim; Yong Chan Ahn; Hee Chul Park; Do Hoon Lim; Heerim Nam
Journal:  J Thorac Oncol       Date:  2010-04       Impact factor: 15.609

View more
  10 in total

Review 1.  Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy?

Authors:  Esengül Koçak Uzel; Ufuk Abacıoğlu
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

2.  Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.

Authors:  Dawn Owen; Kenneth R Olivier; Charles S Mayo; Robert C Miller; Kathryn Nelson; Heather Bauer; Paul D Brown; Sean S Park; Daniel J Ma; Yolanda I Garces
Journal:  Radiat Oncol       Date:  2015-02-18       Impact factor: 3.481

3.  Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors.

Authors:  Takaya Yamamoto; Keiichi Jingu; Yuko Shirata; Masashi Koto; Haruo Matsushita; Toshiyuki Sugawara; Masaki Kubozono; Rei Umezawa; Keiko Abe; Noriyuki Kadoya; Youjirou Ishikawa; Maiko Kozumi; Noriyoshi Takahashi; Ken Takeda; Yoshihiro Takai
Journal:  BMC Cancer       Date:  2014-06-23       Impact factor: 4.430

Review 4.  Oligometastasis and oligo-recurrence: more than a mirage.

Authors:  Fang Huang; Gang Wu; Kunyu Yang
Journal:  Radiat Oncol       Date:  2014-10-31       Impact factor: 3.481

5.  Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?

Authors:  Alina Santiago; Steffen Barczyk; Urszula Jelen; Rita Engenhart-Cabillic; Andrea Wittig
Journal:  Radiat Oncol       Date:  2016-05-06       Impact factor: 3.481

6.  Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases.

Authors:  Ben Man Fei Cheung; Kin Sang Lau; Victor Ho Fun Lee; To Wai Leung; Feng-Ming Spring Kong; Mai Yee Luk; Kwok Keung Yuen
Journal:  Radiat Oncol J       Date:  2021-10-26

7.  A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.

Authors:  Xin Wang; Leonid Zamdborg; Hong Ye; Inga S Grills; Di Yan
Journal:  BMC Cancer       Date:  2018-10-10       Impact factor: 4.430

8.  Correlation of clinical outcome, radiobiological modeling of tumor control, normal tissue complication probability in lung cancer patients treated with SBRT using Monte Carlo calculation algorithm.

Authors:  Sumit S Sood; Damodar Pokhrel; Rajeev Badkul; Mindi TenNapel; Christopher McClinton; Bruce Kimler; Fen Wang
Journal:  J Appl Clin Med Phys       Date:  2020-08-14       Impact factor: 2.102

9.  Identification of novel prognostic factors focusing on clinical outcomes in patients with non-small cell lung cancer after stereotactic body radiotherapy.

Authors:  Hikari Sato; Fumiki Ito; Kazuki Hasegawa; Ryo Saga; Yoichiro Hosokawa; Mitsuki Tanaka; Masahiko Aoki
Journal:  Oncol Lett       Date:  2022-01-11       Impact factor: 2.967

10.  [Radiofrequency Ablation for Lung Ground-glass Nodule].

Authors:  Xiaogang Tan; Baodong Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-10-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.